Abstract
Introduction: Adjuvant chemotherapy with Gem has been shown to decrease disease recurrence and increase survival following surgery in patients with resected pancreatic cancer. However, disease recurrence is common, suggesting a need for improved regimens. In the phase III MPACT trial, nab-P + Gem demonstrated significantly longer overall survival (OS; primary endpoint) than Gem alone in patients with metastatic pancreatic cancer (median, 8.7 vs 6.6 months; HR 0.72; P < 0.001). Toxicities were manageable and consistent with those in previous studies. The findings of the MPACT trial supported the investigation of nab-P + Gem vs Gem alone as adjuvant therapy in the phase III APACT study of patients with resected pancreatic cancer.